The short answer
Stimulants — methylphenidate-based (Concerta, Ritalin, Focalin) and amphetamine-based (Adderall, Vyvanse, Mydayis) — remain first-line for most adults with ADHD. They're the most extensively studied, work most quickly, and produce the largest effect sizes in clinical trials. For most patients, starting with a stimulant is the appropriate choice.
Non-stimulants are the right starting point — or the right switch — in a specific set of clinical situations. They're not a consolation prize. For the right patient, a non-stimulant produces meaningful ADHD symptom improvement without controlled-substance complications, without the appetite suppression, and without the daily on/off rhythm of a stimulant.
When non-stimulants are the better choice
Significant cardiovascular history
Untreated or poorly controlled hypertension, structural heart disease, certain arrhythmias, or a recent cardiac event are reasons to avoid stimulants — at minimum until the cardiac picture is stabilized. Non-stimulants generally have a more favorable cardiac profile, though they're not entirely without cardiac considerations.
Substance use history
For patients with active substance use disorder or significant past stimulant misuse, prescribing a Schedule II stimulant carries real risk. Non-stimulants (none of which are controlled substances) sidestep that.
Severe comorbid anxiety
Stimulants can worsen anxiety in patients who are already in a hyper-aroused state. When anxiety is severe and ADHD is also present, starting with a non-stimulant (or treating the anxiety with an SSRI first) can be a better sequencing.
Sleep problems made worse by stimulants
Some patients try a stimulant and find it works well for focus but destroys their sleep, even with conservative dosing or earlier timing. A non-stimulant — often taken at night — can preserve daytime focus benefit without the sleep cost.
Stimulant intolerance
Some patients simply don't tolerate stimulants well — they feel "wired but not focused," anxious, irritable, or physically uncomfortable. Trying a non-stimulant after one or two failed stimulant trials is reasonable.
Patient preference
Some patients simply prefer a non-controlled-substance approach, often for practical reasons — pharmacy refill complications, controlled-substance documentation at work, the monthly cadence of stimulant prescribing. That's a reasonable preference, and we accommodate it when clinically appropriate.
The main non-stimulant options
Atomoxetine (Strattera)
The first FDA-approved non-stimulant for ADHD. A selective norepinephrine reuptake inhibitor. Effective for both inattentive and hyperactive symptoms, with the slowest onset (4–6 weeks to full effect) but durable around-the-clock coverage. Often a good choice when anxiety is comorbid. Common early side effects include nausea, dry mouth, fatigue, and (in a minority of patients) elevated blood pressure.
Viloxazine (Qelbree)
FDA-approved for adults in 2022. Also a norepinephrine reuptake inhibitor, with a slightly different pharmacologic profile than atomoxetine — some patients tolerate one better than the other. Onset is moderate (2–4 weeks). Side effects can include sleepiness, headache, and decreased appetite.
Bupropion (Wellbutrin)
Not FDA-approved specifically for ADHD, but used off-label with reasonable evidence. A dopamine and norepinephrine reuptake inhibitor. Often a good choice when ADHD coexists with depression or with seasonal mood patterns; not a good choice for patients with significant anxiety, seizure history, or eating disorders. Onset is 2–4 weeks.
Guanfacine ER (Intuniv)
An alpha-2A adrenergic agonist, originally a blood-pressure medication. FDA-approved for pediatric ADHD; used off-label in adults, often as an adjunct to a stimulant or as a monotherapy when anxiety or sleep difficulties are prominent. Can be sedating. Works on a different neurochemical pathway than the stimulants and atomoxetine.
Clonidine
Similar mechanism to guanfacine but shorter-acting and more sedating. More often used at bedtime to help with the sleep disruption that ADHD often produces, rather than as a daytime ADHD treatment.
How they compare to stimulants
Effect size
Across head-to-head trials and meta-analyses, stimulants produce larger effect sizes on core ADHD symptoms than non-stimulants. The practical translation: more patients respond to a stimulant, and the average degree of improvement is larger. That doesn't mean non-stimulants don't work — for many patients they work well — just that the average response is somewhat smaller.
Onset
Stimulants work the same day. Non-stimulants take weeks. This is the single largest practical difference and the reason patients often try stimulants first.
On/off rhythm
Stimulants produce a daily on/off rhythm — focus rises after dosing, peaks for several hours, then drops off. Non-stimulants produce steadier, more uniform coverage across the day, including evenings and weekends.
Controlled-substance status
All Schedule II stimulants require monthly written prescriptions, can't be auto-refilled, and have periodic supply variability. Non-stimulants are dispensed like any other prescription.
Cost
Generic stimulants are often very cheap; generic atomoxetine is also affordable. Brand-name non-stimulants (Qelbree, brand Intuniv) can be expensive without insurance coverage.
Side effects to expect
The non-stimulants share some general patterns and have some specific ones:
- Atomoxetine and viloxazine: Most commonly cause nausea, dry mouth, fatigue, and (occasionally) blood-pressure elevation. Sexual side effects are possible.
- Bupropion: Can cause insomnia, dry mouth, headache, and (rarely) anxiety or seizures. Generally activating rather than sedating, which is helpful for low-energy depression but unwelcome for anxious patients.
- Guanfacine and clonidine: Sedation is the main side effect — usually a feature when used at bedtime, sometimes a bug when used during the day. Can also lower blood pressure.
Combining non-stimulants with stimulants
For some patients, a stimulant plus a non-stimulant works better than either alone. A common configuration: a stimulant during the day for daytime focus, plus guanfacine at bedtime for sleep and to take the edge off late-day rebound. Another: atomoxetine for steady background coverage, with a shorter-acting stimulant added on days that require peak focus. Combinations are clinically reasonable when monotherapy isn't quite enough, but we discuss the rationale and trade-offs explicitly.
Frequently asked questions
Will I have to try a stimulant first before getting a non-stimulant?
No. There's no clinical or regulatory requirement to fail a stimulant first. If a non-stimulant is the right starting point for your situation, that's where we start.
How long until I know if a non-stimulant is working?
Atomoxetine: 4–6 weeks at a therapeutic dose. Viloxazine and bupropion: 2–4 weeks. Guanfacine: 2 weeks. None work as quickly as a stimulant, which is the main practical trade-off.
Can I drink alcohol on a non-stimulant?
Moderate alcohol use is not absolutely contraindicated with most non-stimulants. Bupropion has a slightly elevated seizure risk that's worth discussing if you drink heavily. Always best to discuss with your prescriber.
Are non-stimulants safer than stimulants?
Not necessarily — both classes have well-characterized safety profiles. Non-stimulants avoid the specific risks of stimulants (cardiovascular concerns at high doses, misuse potential, appetite suppression), but they have their own profile (atomoxetine has a black-box warning for suicidal thoughts in young adults; bupropion can lower the seizure threshold). 'Safer' depends on your individual clinical picture.
If a non-stimulant doesn't work, can I switch to a stimulant?
Yes. Switching between classes is common and clinically straightforward. The reverse is also true — patients who started on stimulants sometimes switch to non-stimulants for tolerability.